Lowering metabolism may help preserve vulnerable brain tissue.
BEIJING, China | June 2026
Researchers have tested a pharmacological form of controlled hibernation in conscious patients after ischemic stroke, exploring whether two established drugs can lower body temperature and slow metabolism without external cooling. The experimental approach combines promethazine and chlorpromazine, a pairing referred to as C+P. Scientists hope that reducing the brain’s energy requirements during the acute phase of a stroke could limit damage caused by interrupted blood flow. The first human trial primarily evaluated safety rather than proving clinical effectiveness.
An ischemic stroke occurs when a blood clot blocks an artery supplying the brain. Neurons deprived of oxygen and glucose begin to fail rapidly, making treatment time critical. Current therapies focus on restoring circulation through clot-dissolving medication or mechanical thrombectomy. Even after blood flow returns, however, inflammation, metabolic stress and cellular injury can continue damaging brain tissue.
Therapeutic cooling has long attracted interest as a possible form of neuroprotection. Lower temperatures reduce cellular metabolism, decreasing the amount of oxygen and energy required by vulnerable tissue. The principle resembles the survival strategy used by hibernating mammals, whose bodies enter a state of reduced temperature and metabolic activity. Applying that effect safely to awake stroke patients has remained difficult.
Physical cooling methods can include chilled blankets, ice packs, cooling helmets or internal temperature-control devices. These techniques may cause shivering, discomfort and physiological responses that work against the intended temperature reduction. Shivering generates heat and increases metabolic demand, potentially limiting the protective value of cooling. More invasive methods can also complicate emergency treatment and require specialized equipment.
The research team, led by Shuaili Xu at Capital Medical University, investigated whether medication could induce a tolerable reduction in temperature without those reactions. Promethazine and chlorpromazine both act on the central nervous system and are already used for other medical purposes. In combination, they can influence the body’s temperature regulation and suppress the metabolic response that normally resists cooling. This makes pharmacological hypothermia conceptually different from forcing the body to become cold from the outside.
Preclinical studies produced stronger effects than the initial human trial. In mice and rhesus monkeys, the drug combination reduced body temperature to approximately 33 to 34 degrees Celsius. It also slowed glucose metabolism and limited the extent of brain injury after experimentally induced stroke. Treated animals showed better motor recovery than untreated comparison groups.
Those results justified moving into a phase I clinical trial involving patients with ischemic stroke. Participants received standard stroke care together with either the experimental drug combination or a placebo. The researchers tested different doses while monitoring temperature, blood pressure, breathing and neurological recovery. Because this was an early-stage study, the central objective was to determine whether the treatment could be administered without causing unacceptable harm.
The highest tested dose, 100 milligrams, produced a modest reduction in body temperature and appeared to slow metabolism. Patients were followed for 90 days, and those receiving the largest dose generally showed favorable recovery without serious complications such as dangerous hypotension or respiratory failure. These findings provided an initial indication that the combination could be tolerated in this setting. They did not establish that the treatment prevented disability or reduced the size of the stroke.
The temperature reduction in humans was only about 0.3 degrees Celsius. That change was far smaller than the reduction achieved in animal studies and was insufficient to demonstrate meaningful protection of brain tissue. The researchers believe the 12-hour intravenous infusion may have delivered the drugs too slowly to create the desired metabolic state. A faster or differently structured administration schedule could potentially produce a stronger effect.
The limited temperature change is an important reminder that encouraging laboratory results do not automatically translate into clinical success. Human patients differ widely in age, stroke severity, other illnesses and medications. Safety requirements also limit how aggressively researchers can reduce temperature or alter consciousness. Any future treatment must provide measurable neurological benefit without delaying established emergency therapies.
The use of promethazine and chlorpromazine also requires careful monitoring. Both drugs can cause sedation, blood-pressure changes and other effects on the nervous and cardiovascular systems. Chlorpromazine, in particular, has a long history of clinical use but can produce significant adverse reactions depending on dose and patient condition. Researchers must determine whether the potential neuroprotective benefits outweigh those risks in acutely ill patients.
Further trials will need to include larger groups and more detailed comparisons. Investigators must establish the most effective dose, the optimal infusion speed and the time window after stroke in which treatment remains useful. They will also need brain imaging and functional assessments to determine whether the intervention actually preserves tissue. Safety data alone cannot support routine clinical use.
The concept could eventually extend beyond stroke if researchers learn to control metabolism reliably. Severe trauma, cardiac arrest, sepsis and other critical conditions can produce tissue damage when oxygen delivery becomes inadequate. Temporarily reducing metabolic demand could give physicians more time to restore circulation or treat the underlying cause. Such applications remain theoretical until larger human studies confirm both safety and effectiveness.
Pharmacological hibernation should not be confused with suspended animation. The goal is not to place patients into a prolonged unconscious state or stop normal biological activity. Instead, researchers are attempting to create a mild, controlled reduction in temperature and energy consumption during a short medical emergency. The intended effect is protective slowing, not complete shutdown.
The first trial therefore represents a proof of feasibility rather than a therapeutic breakthrough. It showed that the drug combination could be administered to conscious stroke patients without the severe complications researchers feared most. It also revealed that the metabolic effect was too small to reduce brain damage significantly under the tested conditions. That combination of reassurance and limitation will shape the next phase of investigation.
Stroke treatment remains governed by speed, and no experimental cooling strategy replaces urgent medical care. Patients still require rapid diagnosis, imaging and restoration of blood flow whenever possible. Pharmacological hibernation could eventually become an additional protective layer after those essential steps. For now, it remains an early scientific attempt to give the injured brain something it rarely receives during a stroke: more time.
Innovation matters most when caution leads the way. / La innovación importa más cuando la cautela marca el camino.